Elaine elisabetsky, phd, member of jaguar health's mental health entheogen therapeutics initiative, to speak august 2nd about plant-based medicines used to manage schizophrenia at the university of illinois chicago college of pharmacy

Dr. elisabetsky is also an advisor to magdalena biosciences , the joint venture formed by jaguar and filament health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions as announced , jaguar recently executed an out-license deal with magdalena biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with potential corporate partners; the global schizophrenia treatment market valued at $8.29 billion san francisco, ca / accesswire / august 2, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that elaine elisabetsky, phd, is conducting a talk on friday, august 2, 2024 from 12:30 pm - 2:00 pm central covering several decades of research on plant-based medicines used to manage schizophrenia. dr. elisabetsky's talk is part of the annual norman r.
JAGX Ratings Summary
JAGX Quant Ranking